These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15485005)

  • 1. Cyclophosphamide in systemic sclerosis: light and shadows.
    Vlachoyiannopoulos PG; Ioannidis JP
    Clin Exp Rheumatol; 2004; 22(5):551-2. PubMed ID: 15485005
    [No Abstract]   [Full Text] [Related]  

  • 2. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?
    Wells AU; Latsi P; McCune WJ
    Am J Respir Crit Care Med; 2007 Nov; 176(10):952-3. PubMed ID: 17984310
    [No Abstract]   [Full Text] [Related]  

  • 3. Educational case report - self assessment.
    Walker T
    Cytopathology; 2002 Oct; 13(5):329. PubMed ID: 12421450
    [No Abstract]   [Full Text] [Related]  

  • 4. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung fibrosis in systemic sclerosis treated with a combination of ciclosporin and azathioprine.
    Hider SL; Woodhead M; Taylor PM; Bruce IN
    Clin Exp Rheumatol; 2006; 24(2):215. PubMed ID: 16762168
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
    Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
    Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 8. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold?
    Baughman RP; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):2-3. PubMed ID: 18096712
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
    Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
    J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events during the Scleroderma Lung Study.
    Furst DE; Tseng CH; Clements PJ; Strange C; Tashkin DP; Roth MD; Khanna D; Li N; Elashoff R; Schraufnagel DE;
    Am J Med; 2011 May; 124(5):459-67. PubMed ID: 21531236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
    Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
    Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide.
    Akesson A; Scheja A; Lundin A; Wollheim FA
    Arthritis Rheum; 1994 May; 37(5):729-35. PubMed ID: 8185701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
    Behr J; Vogelmeier C; Beinert T; Meurer M; Krombach F; König G; Fruhmann G
    Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):400-6. PubMed ID: 8756813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients.
    Becker MO; Schohe A; Weinert K; Huscher D; Schneider U; Burmester GR; Riemekasten G
    Ann Rheum Dis; 2012 Dec; 71(12):2061-2. PubMed ID: 22689320
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pulmonary arterial hypertension in collagen disease: experiences of the German Network for Systemic Scleroderma].
    Hunzelmann N; Riemekasten G
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S325-7. PubMed ID: 17139598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide in scleroderma lung disease.
    Sullivan KM; McSweeney PA; Nash RA
    N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
    [No Abstract]   [Full Text] [Related]  

  • 17. Scleroderma lung disease: "if you don't know where you are going, any road will take you there".
    Strange C; Seibold JR
    Am J Respir Crit Care Med; 2008 Jun; 177(11):1178-9. PubMed ID: 18487619
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.
    Vallance DK; Lynch JP; McCune WJ
    Curr Opin Rheumatol; 1995 May; 7(3):174-82. PubMed ID: 7612408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in the treatment of scleroderma].
    Marquet R; Vilardell M
    Med Clin (Barc); 1984 Jun; 83(2):74-7. PubMed ID: 6147448
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclophosphamide in scleroderma lung disease.
    Andreu JL; Silva L
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.